Biotechnology Amgen (Nasdaq: AMGN), the world's largest independent biotech company, announced top-line results on Friday of the Phase III EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar (cinacalcet, sold as Mimpara in Europe) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis, which failed to meet its primary endpoint. 11 June 2012